Table 1.
Demographics characteristics and humoral response rates of the study population and comparison between previously infected and not previously infected.
| Variable | Total (n = 252) | Previously Infected (n = 121) | Not Previously Infected (n = 131) | p-Value |
|---|---|---|---|---|
| Age, years * (IQR) | 35 (29–45) | 35 (29.5–45) | 35.5 (29–46) | 0.914 a |
| Sex (%) | 0.269 b | |||
| - Female | 203 (80.55) | 94 (46.31) | 109 (53.69) | |
| - Male | 49 (19.45) | 27 (55.10) | 22 (44.9) | |
| Laboral Area (%) | 0.203 b | |||
| - Phlebotomy | 78 (30.95) | 42 (53.85) | 36 (46.15) | |
| - Customer service | 52 (20.63) | 24 (46.15) | 28 (53.85) | |
| - Maintenance service | 28 (11.11) | 17 (60.71) | 11 (39.29) | |
| - Analytic Process | 35 (13.90) | 12 (34.29) | 23 (65.71) | |
| - Administrative | 59 (23.41) | 26 (44.07) | 33 (55.93) | |
| Working mode (%) | 0.911 b | |||
| - Remote | 35 (14.17) | 17 (48.57) | 18 (51.43) | |
| - Presence | 198 (78.35) | 96 (48.48) | 102 (51.52) | |
| - Both | 19 (7.54) | 9 (47.37) | 10 (52.63) | |
| Days since infection * (IQR) | 231.5 (173–277) | |||
| Humoral response rates ** | ||||
| 21 days after the first dose (%) | ||||
| - SARS-CoV-2 S1 IgM/IgG | 162 (71.68) | 97 (95.09) | 65 (52.41) | <0.001 b |
| - Anti-SARS-CoV-2-N | 117 (49.16) | 110 (98.21) | 7 (5.56) | <0.001 c |
| - Seroconversion | 176 (73.95) | 111 (99.10) | 65 (51.59) | <0.001 c |
| 21 days after the second dose (%) | ||||
| - SARS-CoV-2-S1 IgM/IgG | 241 (95.63) | 121 (100) | 120 (91.60) | <0.001 b |
| - Anti-SARS-CoV-2 N | 211 (88.66) | 121 (100) | 90 (68.70) | <0.001 c |
| - Elecsys® anti-SARS-CoV-2 S | 248 (98.41) | 121 (100) | 127 (96.94) | 0.071 c |
| - Ab neutralization cPass™ | 222 (95.28) | 106 (99.06) | 116 (92.06) | 0.013 c |
| - Seroconversion | 241 (95.63) | 121 (100) | 120 (91.60) | <0.001 c |
| 90 days after the second dose (%) | ||||
| - Elecsys® anti-SARS-CoV-2 S | 224 (99.56) | 109 (100) | 115 (99.14) | 0.516 c |
| - Ab neutralization cPass™ | 196 (87.11) | 109 (100) | 87 (75) | <0.001 c |
| 180 days after second dose (%) | ||||
| - Elecsys® anti-SARS-CoV-2 S | 224 (99.56) | 113 (100) | 111 (99.11) | 0.498 c |
| - Ab neutralization cPass™ | 164 (72.89) | 111 (98.23) | 53 (47.32) | <0.001 c |
* Median and interquartile range; a U-Mann–Whitney; b χ2; c Fisher’s exact. IQR: Interquartile range. ** The distribution of the humoral response percentages was calculated based on the population described in Figure 1.